Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04716231 · ClinicalTrials.gov registry record · Phase 3
Atacicept in Subjects With IgA Nephropathy
A Phase 3 study of IgA Nephropathy and Berger Disease, sponsored by Vera Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
- 1
- Study location
NCT04716231: Active Phase 3 study of IgA Nephropathy and Berger Disease, sponsored by Vera Therapeutics.
NCT04716231 is a Phase 3 study of IgA Nephropathy and Berger Disease that is active but no longer recruiting, run by Vera Therapeutics. The registered enrollment target is 376 participants, above the 130-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (189% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04716231, a Phase 3 study of IgA Nephropathy and Berger Disease, is active but no longer recruiting, sponsored by Vera Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
Primary Outcome
UPCR based on 24 hour urine collection
Conditions Studied
Interventions
- BIOLOGICAL Atacicept
- OTHER Placebo to match Atacicept
Study Locations (1)
California
- ORIGIN 3 Global Site Contact Information - Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
What the registry record for NCT04716231 still lists
NCT04716231 is an interventional study that assigns participants to a tested intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, above the 130-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (189% higher).
The record links to 2 conditions, with IgA Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Atacicept is the first listed.
NCT04716231 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04716231 about?
NCT04716231 is a clinical study titled "Atacicept in Subjects With IgA Nephropathy". A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
What is the current status of trial NCT04716231?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2023-06-29. Estimated completion is 2028-07.
What conditions does trial NCT04716231 study?
This clinical trial studies the following conditions: IgA Nephropathy, Berger Disease.
What interventions are being tested in trial NCT04716231?
The interventions under investigation include: Atacicept (BIOLOGICAL), Placebo to match Atacicept (OTHER).
Who is sponsoring clinical trial NCT04716231?
This trial is sponsored by Vera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04716231 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgA Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04716231's enrollment target sits among peer trials
376 3rd of 10 higher than 8 of 10 other IgA Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other IgA Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atrasentan in Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zigakibart in Adults With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Study of BHV-1400 in IgA Nephropathy
RECRUITING · Phase 1
-
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
RECRUITING · Phase 2
-
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
RECRUITING · Phase 4
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
- NCT05912647 · 376 participants · NA
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
- NCT05963971 · 376 participants · NA
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI